[Dangerous liaisons in prostate cancer. Clinical and biological implications of recurrent gene fusions].
Prostate cancer is a common and clinically heterogeneous disease. Understanding the biology of prostate cancer is necessary to best determinate the risk of disease progression and develop novel therapeutic approaches to prevent or slow down disease progression. The recent discovery and subsequent characterization of recurrent gene rearrangements of ETS genes - most frequently ERG - in the majority of prostate cancers is a milestone in translational prostate cancer research. Although multiple molecular alterations have been detected in prostate cancer, a detailed understanding of gene fusion in prostate cancer should help explain the clinical and biologic diversity in addition to providing a rationale for a molecular sub-classification of the disease. This review describes the path from the identification of common ETS gene rearrangements in prostate cancer to possible applications in the treatment of patients, on to the potential scientific implications arising from their discovery.
Perner
S
S
Institut für Pathologie, Comprehensive Cancer Center, Universitätsklinikum Tübingen, Liebermeisterstr. 8, 72076 Tübingen. sven.perner1972@gmail.com
D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000473:pathology; D005091:Exons / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D015321:Gene Rearrangement / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008297:Male; D050596:Oncogene Fusion / Q000235:genetics*; D011379:Prognosis; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology*; D050783:Proto-Oncogene Proteins c-ets / Q000235:genetics*; D012697:Serine Endopeptidases / Q000235:genetics*; D015534:Trans-Activators / Q000235:genetics*; D000071230:Transcriptional Regulator ERG
C072312:ERG protein, human; D050783:Proto-Oncogene Proteins c-ets; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG; D012697:Serine Endopeptidases; C421305:TMPRSS2 protein, human
Histopathology. 2010 Jun;56(7):937-43
20636794
Neoplasia. 2008 Mar;10(3):298-302
18320074
Eur Urol. 2009 Aug;56(2):275-86
19409690
Mod Pathol. 2010 Aug;23(8):1061-7
20473283
Urology. 2010 Apr;75(4):762-7
20018353
Am J Surg Pathol. 2007 Jun;31(6):882-8
17527075
Urology. 2007 Oct;70(4):630-3
17991527
Clin Cancer Res. 2008 Jun 1;14(11):3380-5
18519767
Oncogene. 2007 Jul 5;26(31):4596-9
17237811
Prostate. 2001 Sep 15;48(4):285-91
11536308
Histopathology. 2011 Jun;58(7):1028-36
21707704
Nature. 2007 Aug 2;448(7153):561-6
17625570
Mutat Res. 2000 Apr;462(2-3):247-53
10767636
Science. 2005 Oct 28;310(5748):644-8
16254181
Oncogene. 2008 Jan 10;27(3):253-63
17637754
J Natl Cancer Inst. 2008 Jun 4;100(11):815-25
18505969
Nat Genet. 2004 Apr;36(4):331-4
15054488
Cancer Res. 2006 Sep 1;66(17):8337-41
16951139
Cell. 2007 Dec 14;131(6):1190-203
18083107
FEBS Lett. 2004 May 21;566(1-3):169-72
15147889
Nat Rev Cancer. 2007 Apr;7(4):233-45
17361217
Neoplasia. 2006 Oct;8(10):826-32
17032499